• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Corvus Pharmaceuticals Inc.

    5/8/25 5:30:05 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVS alert in real time by email
    S-8 1 tm2514282d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on May 8, 2025

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    Corvus Pharmaceuticals, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of

    incorporation or organization)

     

    46-4670809

    (I.R.S. Employer

    Identification Number)

     

    901 Gateway Boulevard, Third Floor

    South San Francisco, CA 94080

    (650) 900-4520

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

     

     

     

    2016 Equity Incentive Award Plan

    (Full Title of the Plan)

     

     

     

    Richard A. Miller, M.D.

    President and Chief Executive Officer

    Corvus Pharmaceuticals, Inc.

    901 Gateway Boulevard, Third Floor

    South San Francisco, CA 94080

    (650) 900-4520

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Kathleen Wells, Esq.
    Latham & Watkins LLP
    140 Scott Drive
    Menlo Park, CA 94025
    Telephone: (650) 328-4600
    Facsimile: (650) 463-2600

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
    Non-accelerated filer   x   Smaller reporting company   x
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

    Proposed sale to take place as soon after the effective date of the

    registration statement as awards under the plans are exercised and/or vest.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 2,715,991 shares of the Registrant’s common stock issuable under the 2016 Equity Incentive Plan, for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933, 333-255614, 333-264718, 333-270910, and 333-279189) are effective, as a result of the operation of an automatic annual increase provision therein.

     

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON

    FORM S-8

     

    Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 29, 2016, March 10, 2017, March 13, 2018, May 9, 2019, April 30, 2020, April 29, 2021, May 5, 2022, March 28, 2023 and May 7, 2024 (File Nos. 333-210456, 333-216590, 333-223622, 333-231331, 333-237933, 333-255614, 333-264718, 333-270910, and 333-279189) are incorporated by reference herein.

     

     

     

     

    Exhibit Index

           

    Incorporated by Reference

     
       
           

    Filed Herewith

     

    Exhibit
    Number

      Exhibit Description   Form    Date   Number    
    4.1   Amended and Restated Certificate of Incorporation.   8-K   3/29/2016   3.1    
    4.2   Amended and Restated Bylaws.   8-K   3/29/2016   3.2    
    4.3   Form of Common Stock Certificate.   S-1   1/4/2016   4.2    
    5.1   Opinion of Latham & Watkins LLP.               X
    23.1   Consent of independent registered public accounting firm.               X
    23.2   Consent of Latham & Watkins LLP (included in Exhibit 5.1).               X
    24.1   Power of Attorney. Reference is made to the signature page to the Registration Statement.               X
    99.1(a)#   2016 Equity Incentive Award Plan.   S-8   3/29/2016   99.2(a)    
    99.1(b)#   Form of Stock Option Grant Notice and Stock Option Agreement under the 2016 Equity Incentive Award Plan.   S-1   1/4/2016   10.5(b)    
    99.1(c)#   Form of Restricted Stock Award Agreement and Restricted Stock Unit Award Agreement under the 2016 Equity Incentive Award Plan.   S-1   1/4/2016   10.5(c)    
    99.1(d)#   Form of Restricted Stock Unit Award Agreement and Restricted Stock Unit Award Grant Notice under the 2016 Equity Incentive Award Plan.   S-1   1/4/2016   10.5(d)    
    107.1   Calculation of Filing Fee Table               X
                         
        #Indicates management contract or compensatory plan.                

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on this 8th day of May, 2025.

     

      Corvus Pharmaceuticals, Inc.
       
      By:

    /s/ Richard A. Miller

        Richard A. Miller, M.D.
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Richard A. Miller, M.D. and Leiv Lea, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

     

             
    Signature   Title   Date
             

    /s/ Richard A. Miller

     

    Richard A. Miller M.D.

      President, Chief Executive Officer and Director
    (Principal Executive Officer)
      May 8, 2025
             

    /s/ Leiv Lea

     

    Leiv Lea

      Chief Financial Officer
    (Principal Financial and Accounting Officer)
      May 8, 2025
             

    /s/ Ian T. Clark

     

    Ian T. Clark

      Director   May 8, 2025
             

    /s/ Elisha P. (Terry) Gould

     

    Elisha P. (Terry) Gould

      Director   May 8, 2025
             

    /s/ Linda S. Grais, M.D., J.D.

     

    Linda S. Grais, M.D., J.D.

      Director   May 8, 2025
             

    /s/ Scott W. Morrison

     

    Scott W. Morrison

      Director   May 8, 2025
             

    /s/ Peter Thompson, M.D.

     

    Peter Thompson, M.D.

      Director   May 8, 2025
             

    /s/ Richard van den Broek

     

    Richard van den Broek

      Director   May 8, 2025

     

     

    Get the next $CRVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRVS

    DatePrice TargetRatingAnalyst
    1/2/2025$11.00Buy
    H.C. Wainwright
    8/18/2023$7.00Outperform
    Oppenheimer
    12/3/2021$5.00 → $8.00Overweight
    Cantor Fitzgerald
    12/1/2021$8.00Buy
    Jefferies
    8/3/2021$4.00 → $3.50Neutral
    Mizuho
    7/16/2021$9.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Corvus Pharmaceuticals with a new price target

      H.C. Wainwright initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $11.00

      1/2/25 7:32:41 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Corvus Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Corvus Pharmaceuticals with a rating of Outperform and set a new price target of $7.00

      8/18/23 8:04:45 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on Corvus Pharmaceuticals with a new price target

      Cantor Fitzgerald reiterated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $8.00 from $5.00 previously

      12/3/21 9:11:26 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

      Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million Soquelitinib data to be highlighted on conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutica

      5/8/25 4:02:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

      Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate

      5/8/25 4:01:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

      Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the S

      4/23/25 4:08:12 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CRVS
    Leadership Updates

    Live Leadership Updates

    See more
    • President and CEO Miller Richard A Md exercised 559,073 shares at a strike of $3.50, increasing direct ownership by 97% to 1,136,707 units (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/9/25 4:09:21 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Van Den Broek Richard

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      4/9/25 5:26:56 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Van Den Broek Richard claimed ownership of 160,000 shares (SEC Form 3)

      3 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      4/9/25 5:26:25 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company's board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member. "We're thrilled to welcome Richard to our board," said Richard A. Miller, M.D., chairman, president and chief executive officer of Corvus. "Richard has a proven track record in the biotechnology sector and a deep understanding of the global pharmaceutic

      4/9/25 4:01:54 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

      BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara, who is a proven leader with more than 30 years of commercial experience in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio strategy, and new product planning. "Corvus is leading the development of ITK inhibition as a platform opportunity across oncology and immune diseases. The addition of Jeff as chief business officer strengthens our ability to maximize the potential of our ITK programs, both

      2/6/24 4:05:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

      BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediately. His initial focus will be to lead the development of CPI-818, the Company's ITK inhibitor, for the treatment of immune disorders such as T cell lymphomas, autoimmune and allergic diseases.  CPI-818 is currently being studied in a Phase 1/1b clinical trial for the treatment of T cell lymphomas, the results of which we believe could support advancing CPI-818 into a global Phase 2 trial. In addition, recent resea

      7/21/22 4:05:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jones William Benton bought $34,624 worth of shares (20,000 units at $1.73), increasing direct ownership by 15% to 153,773 units (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/7/24 5:06:34 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Miller Richard A Md bought $1,000,000 worth of shares (577,634 units at $1.73) (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/7/24 5:05:52 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc.

      SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      8/1/24 9:18:47 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      5/13/24 4:52:14 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Corvus Pharmaceuticals Inc.

      SC 13G - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      5/9/24 5:29:29 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    SEC Filings

    See more
    • SEC Form S-8 filed by Corvus Pharmaceuticals Inc.

      S-8 - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

      5/8/25 5:30:05 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Corvus Pharmaceuticals Inc.

      10-Q - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

      5/8/25 4:06:05 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

      5/8/25 4:02:52 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Financials

    Live finance-specific insights

    See more
    • Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

      Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million Soquelitinib data to be highlighted on conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutica

      5/8/25 4:02:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

      Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate

      5/8/25 4:01:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

      Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the S

      4/23/25 4:08:12 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care